Cormorant Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $401M | Hold |
|
|||||
|
2025
Q1 | $332M | Hold |
|
|||||
|
2024
Q4 | $460M | Hold |
|
|||||
|
2024
Q3 | $428M | Hold |
|
|||||
|
2024
Q2 | $373M | Hold |
|
|||||
|
2024
Q1 | $427M | Hold |
|
|||||
|
2023
Q4 | $513M | Buy |
|
|||||
|
2023
Q3 | $464M | Hold |
|
|||||
|
2023
Q2 | $415M | Buy |
|
|||||
|
2023
Q1 | $147M | Buy |
|
|||||
|
2022
Q4 | $63.7M | Hold |
|
|||||
|
2022
Q3 | $47.1M | Hold |
|
|||||
|
2022
Q2 | $30.9M | Buy |
|
|||||
|
2022
Q1 | $33.3M | Buy |
|
|||||
|
2021
Q4 | $4.25M | Hold |
|
|||||
|
2021
Q3 | $4.28M | Hold |
|
|||||
|
2021
Q2 | $4.45M | Hold |
|
|||||
|
2021
Q1 | $4.39M | Hold |
|
|||||
|
2020
Q4 | $4.74M | Buy |
|